NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies

Molecular Imaging and Biology

Volumn 10, Issue 5, 2008, Pages 271-280

  Spence, Alexander M ^a   Muzi, Mark ^b   Link, Jeanne M ^c   Hoffman, John M ^c   Eary, Janet F ^b   Krohn, Kenneth A ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

3 F 18 fluoro 3 deoxythymidine; FLT; Fluorothymidine; Glioblastoma; Glioma; Positron emission tomography (PET); Proliferation; Safety; Toxicity

Indexed keywords

3' FLUORO 3' DEOXYTHYMIDINE F18; ANTIRETROVIRUS AGENT; NITROSOUREA; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD EXAMINATION; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; METABOLIC PARAMETERS; NEUROLOGIC EXAMINATION; OLIGODENDROGLIOMA; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION NECROSIS; RECURRENT CANCER; TIME; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADULT; BIOLOGICAL MARKERS; CARBON DIOXIDE; CELL PROLIFERATION; CREATINE; DIDEOXYNUCLEOSIDES; DRUG TOXICITY; ELECTROCARDIOGRAPHY; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POTASSIUM; UNITED STATES;

EID: 49149108259     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0151-6     Document Type: Article

References (19)

1. Grierson JR, Shields AF (2000) Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143-156
2. Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
3. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA (2004) Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol 31:829-837
4. Langen P, Etzold G, Hintsche R, Kowollik G (1969) 3′-Deoxy-3′-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol Med Ger 23:759-766
5. Langen P, Graetz H (1972) Cell death resulting from inhibition by 3′-deoxy-3′-fluorothymidine, cytosine-arabinoside, 5-fluoro-2′- deoxyuridine, and hydroxyurea of DNA synthesis in cultured Ehrich ascites carcinoma cells. Studia Biophys 31/32:359-366
6. Langen P, Kowollik G, Etzold G, Venner H, Reinert H (1972) The phosphorylation of 3′-deoxy-3′-fluorothymidine and its incorporation into DNA in a cellfree system from tumor cells. Acta Biol Med Ger 29:483-494
7. Matthes E, Lehmann C, Scholz D, Rosenthal HA, Langen P (1988) Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem Biophys Res Commun 153:825-831
8. Faraj A, Fowler DA, Bridges EG, Sommadossi JP (1994) Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 38:924-930
9. Flexner C, van der Horst C, Jacobson MA, et al. (1994) Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 170:1394-1403
10. Matthes E, Lehmann C, Scholz D, et al. (1987) Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res Commun 148:78-85
11. Sundseth R, Joyner SS, Moore JT, Dornsife RE, Dev IK (1996) The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother 40:331-335
12. Turcotte E, Wiens LW, Grierson JR, Peterson LM, Wener MH, Vesselle H (2007) Toxicology evaluation of radiotracer doses of 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 7:3 Electronic
13. Muzi M, Spence AM, O'Sullivan F, et al. (2006) Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 47:1612-1621
14. Graham MM, Lewellen BL (1993) High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med 34:1357-1360
15. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF (1996) Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 43:2199-2206
16. Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046-2053
17. Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. (1991) Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 4:489-498
18. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA (2005) Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: Mathematical studies. J Nucl Med 46:371-380
19. Graham MM (1997) Physiologic smoothing of blood time-activity curves for PET data analysis. J Nucl Med 38:1161-1168